MEK Inhibition Aids in Serous Ovarian Cancer

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2012年 / 2卷 / 05期
关键词：
D O I：
10.1158/2159-8290.CD-NB2012-029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In a phase II trial of the experimental MEK inhibitor selumetinib (AZD6244), women who had failed 3 or more rounds of chemotherapy had 81% disease control and a median progression-free survival of 11.3 months.
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Notch signaling in serous ovarian cancer
    Jolijn W Groeneweg
    Rosemary Foster
    Whitfield B Growdon
    René HM Verheijen
    Bo R Rueda
    Journal of Ovarian Research, 7
  • [32] Notch signaling in serous ovarian cancer
    Groeneweg, Jolijn W.
    Foster, Rosemary
    Growdon, Whitfield B.
    Verheijen, Rene H. M.
    Rueda, Bo R.
    JOURNAL OF OVARIAN RESEARCH, 2014, 7
  • [33] The highs and lows of serous ovarian cancer
    Grisham, Rachel N.
    Manning-Geist, Beryl L.
    Chui, M. Herman
    CANCER, 2023, 129 (17) : 2613 - 2620
  • [34] Scalp metastasis of a serous ovarian cancer
    Matsui, H
    Suzuka, K
    Yamazawa, K
    Tanaka, N
    Mitsuhashi, A
    Seki, K
    Sekiya, S
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2002, 81 (06) : 577 - 578
  • [35] Sarcopenia in Advanced Serous Ovarian Cancer
    Bronger, Holger
    Hederich, Philipp
    Hapfelmeier, Alexander
    Metz, Stephan
    Noel, Peter B.
    Kiechle, Marion
    Schmalfeldt, Barbara
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (02) : 223 - 232
  • [36] Serous Ovarian Cancer Signaling Pathways
    Kotsopoulos, Ioannis C.
    Papanikolaou, Alexios
    Lambropoulos, Alexandros F.
    Papazisis, Konstantinos T.
    Tsolakidis, Dimitrios
    Touplikioti, Panagiota
    Tarlatzis, Basil C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (03) : 410 - 417
  • [37] Phenotypic heterogeneity in serous ovarian cancer
    Simons, E.
    McClung, C.
    Chen, Y.
    Bieber, M.
    Teng, N.
    GYNECOLOGIC ONCOLOGY, 2012, 127 (01) : S9 - S9
  • [38] Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancer
    Nguyen, Nancy
    Brooks, Rebecca
    Leiserowitz, Gary
    Chien, Jeremy
    GYNECOLOGIC ONCOLOGY, 2022, 164 (01) : E3 - E4
  • [39] MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis
    Musacchio, Lucia
    Valsecchi, Anna Amela
    Salutari, Vanda
    Valabrega, Giorgio
    Camarda, Floriana
    Tuninetti, Valentina
    Giannone, Gaia
    Bartoletti, Michele
    Marchetti, Claudia
    Pignata, Sandro
    Fagotti, Anna
    Scambia, Giovanni
    Di Maio, Massimo
    Lorusso, Domenica
    CANCER TREATMENT REVIEWS, 2022, 110
  • [40] Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
    Han, Chanhee
    Bellone, Stefania
    Zammataro, Luca
    Schwartz, Peter E.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY REPORTS, 2018, 25 : 41 - 44
12345